This inventor holds 1 USPTO granted patent. Top assignee: Interneuron Pharmaceuticals, Inc.. Active years: 1998.
Company Filing History:
Years Active: 1998
Title: Thomas David Steele: Innovator in Dementia Treatment
Introduction
Thomas David Steele is a notable inventor based in Acton, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of dementia. His innovative approach focuses on enhancing cognitive function through the administration of specific pharmaceutical compositions.
Latest Patents
Steele holds a patent for "Dopamine D.sub.1 agonists for the treatment of dementia." This invention provides a method for raising extracellular brain acetylcholine levels to improve cognition. The administration of a dopamine D.sub.1 agonist to warm-blooded animals is central to this method, showcasing his commitment to advancing medical science.
Career Highlights
Steele is associated with Interneuron Pharmaceuticals, Inc., where he applies his expertise in developing treatments for neurological conditions. His work has the potential to impact the lives of many individuals suffering from cognitive impairments.
Collaborations
One of his notable coworkers is Kenneth W Locke, with whom he collaborates on various projects within the pharmaceutical industry.
Conclusion
Thomas David Steele's contributions to dementia treatment through his innovative patent highlight his role as a key figure in the pharmaceutical field. His work continues to pave the way for advancements in cognitive health.